Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naldemedine for opioid-induced constipation in cancer patients
ChiCTR2200061564Phase 4Not yet recruiting
- Sponsor
- Hainan General Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naldemedine in opioid-induced constipation (OIC), sponsored by Hainan General Hospital. Primary endpoint: Spontaneous bowel movement responder rate during the first 2 weeks. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on ChiCTR2200061564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061564.